Inhibition of SREBP transcriptional activity by a boron-containing compound improves lipid homeostasis in diet-induced obesity

Xiaoping Zhao, Alus Michael Xiaoli, Haihong Zong, Arian Abdulla, Ellen S T Yang, Qun Wang, Jun Yuan Ji, Jeffrey E. Pessin, Bhaskar C. Das, Fajun Yang

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Dysregulation of lipid homeostasis is intimately associated with obesity, type 2 diabetes, and cardiovascular diseases. Sterol regulatory-element binding proteins (SREBPs) are the master regulators of lipid biosynthesis. Previous studies have shown that the conserved transcriptional cofactor Mediator complex is critically required for the SREBP transcriptional activity, and recruitment of the Mediator complex to the SREBP transactivation domains (TADs) is through the MED15-KIX domain. Recently, we have synthesized several boron-containing small molecules. Among these novel compounds, BF175 can speci fi cally block the binding of MED15-KIX to SREBP1a-TAD in vitro, resulting in an inhibition of the SREBP transcriptional activity and a decrease of SREBP target gene expression in cultured hepatocytes. Furthermore, BF175 can improve lipid homeostasis in the mouse model of diet-induced obesity. Compared with the control, BF175 treatment decreased the expression of SREBP target genes in mouse livers and decreased hepatic and blood levels of lipids. These results suggest that blocking the interaction between SREBP-TADs and the Mediator complex by small molecules may represent a novel approach for treating diseases with aberrant lipid homeostasis.

Original languageEnglish (US)
Pages (from-to)2464-2473
Number of pages10
JournalDiabetes
Volume63
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Boron Compounds
Sterol Regulatory Element Binding Proteins
Homeostasis
Obesity
Diet
Lipids
Mediator Complex
Transcriptional Activation
Personnel Selection
Boron
Liver
Type 2 Diabetes Mellitus
Hepatocytes
Cardiovascular Diseases
Gene Expression

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Inhibition of SREBP transcriptional activity by a boron-containing compound improves lipid homeostasis in diet-induced obesity. / Zhao, Xiaoping; Xiaoli, Alus Michael; Zong, Haihong; Abdulla, Arian; Yang, Ellen S T; Wang, Qun; Ji, Jun Yuan; Pessin, Jeffrey E.; Das, Bhaskar C.; Yang, Fajun.

In: Diabetes, Vol. 63, No. 7, 2014, p. 2464-2473.

Research output: Contribution to journalArticle

Zhao, Xiaoping ; Xiaoli, Alus Michael ; Zong, Haihong ; Abdulla, Arian ; Yang, Ellen S T ; Wang, Qun ; Ji, Jun Yuan ; Pessin, Jeffrey E. ; Das, Bhaskar C. ; Yang, Fajun. / Inhibition of SREBP transcriptional activity by a boron-containing compound improves lipid homeostasis in diet-induced obesity. In: Diabetes. 2014 ; Vol. 63, No. 7. pp. 2464-2473.
@article{aac3c62a97b24b96928a01aff269d1ca,
title = "Inhibition of SREBP transcriptional activity by a boron-containing compound improves lipid homeostasis in diet-induced obesity",
abstract = "Dysregulation of lipid homeostasis is intimately associated with obesity, type 2 diabetes, and cardiovascular diseases. Sterol regulatory-element binding proteins (SREBPs) are the master regulators of lipid biosynthesis. Previous studies have shown that the conserved transcriptional cofactor Mediator complex is critically required for the SREBP transcriptional activity, and recruitment of the Mediator complex to the SREBP transactivation domains (TADs) is through the MED15-KIX domain. Recently, we have synthesized several boron-containing small molecules. Among these novel compounds, BF175 can speci fi cally block the binding of MED15-KIX to SREBP1a-TAD in vitro, resulting in an inhibition of the SREBP transcriptional activity and a decrease of SREBP target gene expression in cultured hepatocytes. Furthermore, BF175 can improve lipid homeostasis in the mouse model of diet-induced obesity. Compared with the control, BF175 treatment decreased the expression of SREBP target genes in mouse livers and decreased hepatic and blood levels of lipids. These results suggest that blocking the interaction between SREBP-TADs and the Mediator complex by small molecules may represent a novel approach for treating diseases with aberrant lipid homeostasis.",
author = "Xiaoping Zhao and Xiaoli, {Alus Michael} and Haihong Zong and Arian Abdulla and Yang, {Ellen S T} and Qun Wang and Ji, {Jun Yuan} and Pessin, {Jeffrey E.} and Das, {Bhaskar C.} and Fajun Yang",
year = "2014",
doi = "10.2337/db13-0835",
language = "English (US)",
volume = "63",
pages = "2464--2473",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "7",

}

TY - JOUR

T1 - Inhibition of SREBP transcriptional activity by a boron-containing compound improves lipid homeostasis in diet-induced obesity

AU - Zhao, Xiaoping

AU - Xiaoli, Alus Michael

AU - Zong, Haihong

AU - Abdulla, Arian

AU - Yang, Ellen S T

AU - Wang, Qun

AU - Ji, Jun Yuan

AU - Pessin, Jeffrey E.

AU - Das, Bhaskar C.

AU - Yang, Fajun

PY - 2014

Y1 - 2014

N2 - Dysregulation of lipid homeostasis is intimately associated with obesity, type 2 diabetes, and cardiovascular diseases. Sterol regulatory-element binding proteins (SREBPs) are the master regulators of lipid biosynthesis. Previous studies have shown that the conserved transcriptional cofactor Mediator complex is critically required for the SREBP transcriptional activity, and recruitment of the Mediator complex to the SREBP transactivation domains (TADs) is through the MED15-KIX domain. Recently, we have synthesized several boron-containing small molecules. Among these novel compounds, BF175 can speci fi cally block the binding of MED15-KIX to SREBP1a-TAD in vitro, resulting in an inhibition of the SREBP transcriptional activity and a decrease of SREBP target gene expression in cultured hepatocytes. Furthermore, BF175 can improve lipid homeostasis in the mouse model of diet-induced obesity. Compared with the control, BF175 treatment decreased the expression of SREBP target genes in mouse livers and decreased hepatic and blood levels of lipids. These results suggest that blocking the interaction between SREBP-TADs and the Mediator complex by small molecules may represent a novel approach for treating diseases with aberrant lipid homeostasis.

AB - Dysregulation of lipid homeostasis is intimately associated with obesity, type 2 diabetes, and cardiovascular diseases. Sterol regulatory-element binding proteins (SREBPs) are the master regulators of lipid biosynthesis. Previous studies have shown that the conserved transcriptional cofactor Mediator complex is critically required for the SREBP transcriptional activity, and recruitment of the Mediator complex to the SREBP transactivation domains (TADs) is through the MED15-KIX domain. Recently, we have synthesized several boron-containing small molecules. Among these novel compounds, BF175 can speci fi cally block the binding of MED15-KIX to SREBP1a-TAD in vitro, resulting in an inhibition of the SREBP transcriptional activity and a decrease of SREBP target gene expression in cultured hepatocytes. Furthermore, BF175 can improve lipid homeostasis in the mouse model of diet-induced obesity. Compared with the control, BF175 treatment decreased the expression of SREBP target genes in mouse livers and decreased hepatic and blood levels of lipids. These results suggest that blocking the interaction between SREBP-TADs and the Mediator complex by small molecules may represent a novel approach for treating diseases with aberrant lipid homeostasis.

UR - http://www.scopus.com/inward/record.url?scp=84900032893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900032893&partnerID=8YFLogxK

U2 - 10.2337/db13-0835

DO - 10.2337/db13-0835

M3 - Article

C2 - 24608444

AN - SCOPUS:84900032893

VL - 63

SP - 2464

EP - 2473

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 7

ER -